MAP2K7 and colorectal carcinoma: Early-phase trials suggested that alpelisib may benefit patients with PIK3CA-mutant CRC, particularly when combined with other agents, such as anti-EGFR therapies or MEK inhibitors, although several more recent studies reported contradictory findings regarding the synergistic effect [64,65,66,67].